The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer

• Published in: Prostate cancer and prostatic diseases Vol. 20; no. 2; pp. 234 - 240
• Main Authors: Patel, S A, Chen, M-H, Loffredo, M, Renshaw, A, Kantoff, P W, D'Amico, A V
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.06.2017
• Subjects: Aged; Aged, 80 and over; Androgen Antagonists - administration & dosage; Androgen suppression therapy; Androgens; Biomarkers, Tumor - blood; Cancer; Care and treatment; Cause of Death; Comorbidity; Confidence intervals; Deprivation; Failure analysis; Health aspects; Health risks; Humans; Male; Mortality; Proportional Hazards Models; Prostate - pathology; Prostate cancer; Prostate specific antigen; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; Radiation; Radiation therapy; Radiotherapy; Regression analysis; Risk; Risk Assessment; Risk Factors; Statistical analysis; Subgroups
• ISSN: 1365-7852; 1476-5608
• DOI: 10.1038/pcan.2016.74

The optimal management of men with PSA failure following initial prostate cancer (PC) therapy stratified by comorbidity is unknown. We investigated the impact that PSA doubling time (DT) and comorbidity had on the risk of all-cause mortality (ACM), prostate cancer-specific mortality (PCSM) and other-cause mortality (OCM) following PSA failure. Between 1995 and 2001, 206 men with unfavorable-risk PC were randomized to receive radiation therapy alone or in combination with 6 months of androgen deprivation therapy (ADT); 108 men experienced PSA failure and formed the study cohort. Cox and Fine-Gray regression analysis was used to determine whether PSA DT was associated with the risk of ACM and PCSM/OCM, respectively, stratified by comorbidity status using a validated metric. After a median follow-up of 13.71 years following PSA failure, 81 of the 108 men (75%) died. Longer PSA DT was associated with a decreased risk of PCSM in men with no/minimal (adjusted hazard ratio (AHR) 0.33, 95% confidence interval (CI) 0.17-0.65, P=0.001) and moderate/severe comorbidity (AHR 0.014, 95% CI 0.002-0.129, P=0.0002). However, because of the different contributions of the risk of OCM to risk of ACM within comorbidity subgroups, increasing PSA DT was only associated with a decreased risk of ACM in men with no/minimal (AHR 0.69, 95% CI 0.50-0.96, P=0.03) but not moderate/severe comorbidity (AHR 0.95, 95% CI 0.51-1.78, P=0.87). Both the extent of comorbidity and the PSA DT should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure.